Laurence Dequae, 1 Frangois Dabis, 1 and Roger Salamon 1 for the Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA) 3 To assess the role of Mycobacterium tuberculosis disease in human immunodeficiency virus (HIV) infection, the authors compared survival of tuberculosis patients and controls matched on year of HIV diagnosis and CD4+ lymphocyte count. Patients were selected in the Aquitaine Cohort, which follows, since 1985, all patients infected with HIV, aged more than 13 years, in five hospitals. Time of inclusion of controls was the date of diagnosis of tuberculosis for the corresponding tuberculosis patient. Patients who had received primary prophylaxis against mycobacteria other than tuberculosis were excluded. As of June 30, 1994 , 104 tuberculosis patients and 620 controls were selected; they were similar, except for history of intravenous drug use (tuberculosis patients, 51%, vs. controls, 31%) and AIDS-defining opportunistic infection (40 vs. 29%). Survival was shorter in tuberculosis patients than in controls (risk ratio 1.5, 95% confidence interval 1.2-2.1) even after controlling for differences at entry. The risk of AIDS-defining opportunistic infection or a decrease to fewer than 50 CD4+ cells/mm 3 was slightly but not statistically greater in tuberculosis patients than in controls. Tuberculosis disease affected survival but not occurrence of subsequent opportunistic infections or rate of CD4+ count decline. Tuberculosis may be a marker of advanced HIV and may accelerate its course of infection. Am J Epidemiol 1997;145:293-300.
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The incidence of reported Mycobacterium tuberculosis disease has been increasing worldwide since the beginning of the 1980s (1, 2) . Studies have suggested that this trend was closely related to the human immunodeficiency virus (HIV) pandemic (3, 4) . By mid-1994, the World Health Organization estimated that 5.6 million individuals were infected with both HIV and M. tuberculosis worldwide (2) . The effect of HIV infection on the reactivation of tuberculosis is now well recognized (3) (4) (5) . Consequently, since January 1993, the Centers for Disease Control has expanded the AIDS case definition to pulmonary tuberculosis disease (6) . Tuberculosis is now a major cause of death among HIV-infected patients (7) (8) (9) (10) .
Nevertheless, data are sparse on the effect of tuberculosis disease on the natural history of HIV infection (11, 12) . Several authors have suggested that tuberculosis disease may be an independent marker of ad-vanced immunosuppression in HIV-infected patients, but that it could also be a cofactor in accelerating the course of HIV infection (8, (13) (14) (15) . The containment of tubercle bacilli within a granuloma requires the generation of cytokines, including tumor necrosis factor a. Tumor necrosis factor a may enhance HIV replication, which in turn may increase the viral burden, leading to a faster evolution to clinical acquired immunodeficiency syndrome (AIDS) and death (16) (17) (18) . However, only one epidemiologic study (19) , controlling for the degree of immunodepression, suggested a faster evolution of HFV infection in tuberculosis patients than in patients without tuberculosis disease.
Several issues that are important from a clinical viewpoint for improving care of HIV-infected patients remain unanswered (12, 20) . Whereas systematic prophylaxis against tuberculosis is recommended for all purified protein derivative-positive HIV-infected persons (21) , this recommendation is not routinely applied in other countries. In countries of high HIV and tuberculosis prevalence, indications of systematic preventive therapy against tuberculosis disease should be based on cost effectiveness evaluations, taking into account both the risk of developing resistance strains after preventive therapy and the number of active tuberculosis actually avoided in the long term (11, 12, 22, 23) . If tuberculosis accelerates HIV progression, then an argument exists for a more active prevention of tuberculosis.
Answering this kind of question requires a carefully designed observational study, based on a large and representative cohort with a sufficient follow-up. The Aquitaine Cohort, followed since 1985 by the Groupe d'Epide"miologie Clinique du Sida en Aquitaine (GECSA), is based on a hospital-based surveillance system of HTV infection, set up in the Bordeaux University Hospital and four public hospitals of Aquitaine (24, 25) . The purpose of our study was to assess the effect of tuberculosis disease on the course of HTV infection in the Aquitaine Cohort.
MATERIALS AND METHODS
Aquitaine is a region in southwestern France, with 2,750,000 inhabitants (1990 census); 65 percent of the population lives in urban areas (26) . As of December 31, 1994 , the rate of notified AIDS was 57.8 per 100,000 inhabitants (27) . Subjects in our study were part of the Aquitaine Cohort in which inclusion was retrospective before October 1987 and prospective after that time. Inclusion criteria were 1) HIV-1 infection confirmed by Western blot analysis, regardless of the clinical stage; 2) age more than 13 years; and 3) informed consent. According to mandatory reporting of AIDS cases to the French Ministry of Health, more than 75 percent of AIDS cases in Aquitaine are reported by physicians participating in the GECSA (25) . Participating clinicians have been enrolling and following their patients using standardized computerized epidemiologic, medical, and biologic records. Follow-up is repeated at least every 6 months, and a repeated search for patients lost to follow-up is carried out on a yearly basis.
For the present study, we performed an historical analysis comparing patients who had received diagnoses of tuberculosis disease with controls unexposed to tuberculosis disease. To identify cases of pulmonary and extrapulmonary tuberculosis disease among all patients in the cohort, we used records completed by clinicians during follow-up. Tuberculosis disease was defined as a proven or definite case of tuberculosis disease according to Centers for Disease Control criteria (28), i.e., presence of symptoms consistent with active tuberculosis, associated with a positively confirmed M. tuberculosis culture. Probable or possible cases of tuberculosis disease were excluded from the study. Organ involvement, biologic features, and histologic results, when available, were documented and investigated. Moreover, to make an exhaustive study of proven tuberculosis disease cases in HTVseropositive patients, we reviewed all records from the Department of Microbiology of the Bordeaux University Hospital during the study period. This laboratory receives mycobacterial strains for identification from other public and private microbiology laboratories in the Aquitaine region. Laboratory files of patients in M. tuberculosis isolation were cross-checked with computerized files of patients included in the cohort. All of our tuberculosis patients were treated as recommended in France, beginning with 2 months of a daily combination of rifampicin, isoniazid, ethambutol, and pyrazinamide, followed by at least 4 months of a daily combination of isoniazid and rifampicin.
Although tuberculosis appeared on the death certificates, we checked the causes of death reported on death certificates against the medical records extracted from the GECSA database corresponding to the last clinical follow-up of the patient. Autopsy data were unavailable. Death with tuberculosis was evoked for all patients with a proven or definite case of tuberculosis disease for whom the death certificate and the last medical record reported they had tuberculosis. Classification of deaths related to tuberculosis was made as follows: A definite tuberculosis death was defined for patients without a history of other ATDS-related disease (inaugural AIDS event) and without another known cause of death; a probable tuberculosis death was defined for patients with a history of an ADDS-Tuberculosis Disease and Human Immunodeficiency Virus Infection 295 related disease but without another known current AIDS-related disease at time of death; a possible tuberculosis death was defined for patients with other known current AIDS-related disease at time of death; otherwise, tuberculosis death was excluded.
For each tuberculosis case, we selected in the cohort database all possible controls who had 1) the same year of HTV diagnosis (±6 months), 2) the same time interval between HIV diagnosis and inclusion in our study (±3 months), and 3) the same level of CD4+ lymphocyte count (±25/mm 3 ) at inclusion in our study. CD4+ lymphocyte counts were taken into account at the time of tuberculosis. Time of inclusion of a tuberculosis patient was the date of diagnosis of tuberculosis disease for the tuberculosis patient and the time of CD4+ lymphocytes count for his/her controls. Exclusion criteria were either no follow-up after the inclusion date or primary prophylaxis against M. tuberculosis or mycobacteria other than tuberculosis, and these criteria were intended to exclude patients with a greater risk of resistance to tuberculosis treatment.
We extracted from the GECSA database sociodemographic characteristics, dates of occurrence of opportunistic infections defined according to the 1986 Centers for Disease Control classification system for HTV infection (29) , CD4+ lymphocyte counts, treatments received, and dates and causes of death reported on the death certificates. With death as the primary outcome of this study, the incidence of a new ATDSdefming opportunistic infection and of a decrease to fewer than 50 CD4+ cells/mm 3 were secondary outcomes for the subgroup of patients who were free of these events at inclusion in our study.
We compared baseline characteristics (sociodemographic and risk behavior, history of opportunistic infections, treatment of HIV infection, and CD4+ lymphocyte count) in tuberculosis patients and controls using Chi-square and Student's t tests. Incidence density rates of outcomes were defined as the number of new events per 100 person-years of follow-up (30) . Follow-up for a patient was defined as the period from inclusion to June 30, 1994 , or to the date of the last visit before this study endpoint or the patient's death. The potential follow-up for assessing event-free probabilities was the maximum theoretical participation time of all patients until June 30, 1994 , minus the period between the occurrence of an outcome (death, opportunistic infection, decrease to fewer than 50 CD4+ cells/mm 3 ) and June 30, 1994 . The rate of follow-up was calculated by dividing the actual participation time of all individuals by the potential follow-up period (31) . Event-free cumulative probabilities for survival, opportunistic infections, and a decrease to fewer than 50 CD4+ cells/mm 3 over time were assessed using the Kaplan-Meier method and were reported with their 95 percent confidence intervals (32) . Comparisons of survival curves were assessed with the generalized log rank test. Ninety-five percent confidence intervals around the risk ratio were calculated using Rothman's approximate method (30) . To take into account the effect on mortality of differences between baseline characteristics not controlled for by the matching method and the effect of known prognostic factors of HTV disease progression, a proportional hazard model regression was performed (33) . Variables considered in-the model were tuberculosis disease, age, intravenous drug use, history of opportunistic infection, use of preventive and antiretroviral treatments, and variables of the matching procedure (year of HTV diagnosis, interval between HTV diagnosis and inclusion in the study, and baseline CD4+ lymphocyte count).
RESULTS
As of June 30, 1994, 3,697 patients have been enrolled in the Aquitaine Cohort. Tuberculosis disease was reported in 193 patients (5.2 percent), of whom 104 (53.8 percent) were definite cases meeting inclusion criteria. Tuberculosis was pulmonary in 65 of these cases (62.5 percent), extrapulmonary in 19 (18.3 percent), and disseminated in 20 (19.2 percent). A total of 620 patients met the criteria for inclusion as controls. Tuberculosis patients and controls had a similar median year of HTV diagnosis (1988) and mean interval between HIV diagnosis and inclusion in our study (32.4 months; standard deviation 27.6 months). Mean age was 37.0 years (standard deviation 10.1 years) in tuberculosis patients and 37.5 years (standard deviation 11.1 years) in controls (p = 0.26). Tuberculosis patients were more likely than controls to have a history of intravenous drug use or opportunistic infection (table 1) .
Follow-up was comparable in the two groups (table  2) . Of the 307 patients (42.4 percent) who died, 57 were tuberculosis patients. Sixty-two tuberculosis patients and 441 controls were at risk of developing an AIDS-defining opportunistic infection; 70 tuberculosis patients and 405 controls were at risk of a decreased count of fewer than 50 CD4+ cells/mm 3 . Mortality rates were higher in tuberculosis patients than in controls (40.7/100 vs. In non-intravenous drug users, mortality rates were higher in the 51 tuberculosis patients than in the 426 controls (RR = 1.9, 95 percent CI 1.3-2.7; p = 0.0008) (figure 1). For intravenous drug users, mortality was not different for the 53 tuberculosis patients and 194 controls (RR = 1.3, 95 percent CI: 0.9-2.1; p = 0.14). In patients without a history of AIDSdefining opportunistic infection at inclusion, mortality was higher in the 62 tuberculosis patients than in the 441 controls (RR = 1.5, 95 percent CI 1.1-2.3; p = 0.04) (figure 1). In patients with a history of opportunistic infection at inclusion, mortality for the 42 tuberculosis patients was higher, but not significant, than for the 179 controls (RR = 1. tuberculosis disease, a CD4+ lymphocyte count of fewer than 200 cells/mm 3 , aging, a history of at least one AIDS-defining opportunistic infection, and absence of prolonged treatment after mycobacteria other than tuberculosis were factors strongly associated with mortality in the multivariate analysis (table 3) .
Among the 57 tuberculosis patients who died, the cause of death on the death certificates could be related to tuberculosis for 19.3 percent (11 patients), to AIDS-defining opportunistic infections other than tuberculosis for 33.4 percent, to AIDS-defining events other than opportunistic infections for 36.8 percent, and to other causes for 10.5 percent. Twenty-four percent of tuberculosis patients died within the first month and 64.9 percent within the first year of tuberculosis disease diagnosis. Among the 11 patients for whom the cause of death could be related to tuberculosis disease, five were classified as definite cases, one as a probable case, and five as possible cases according to our case definition. The median survival for these 11 patients was 21 days.
Incidence rates of opportunistic infections were not significantly higher in tuberculosis patients than in controls (28.1/100 vs. 
DISCUSSION
This historical cohort study comparing 104 HTVinfected patients exposed to tuberculosis disease matched with 620 HIV-infected patients unexposed to tuberculosis disease allowed us to assess the effect of tuberculosis disease on the natural history of HIV infection. The main finding was a significant overall reduced survival in patients exposed to tuberculosis disease compared with controls, even when adjusting for variables known to be associated with survival. This difference was particularly marked in patients with a baseline CD4+ lymphocyte count of fewer than 200 cells/mm 3 . In addition, tuberculosis patients had a higher rate of AIDS-defining opportunistic infections and a marked decline of CD4+ lymphocyte count than controls, but these differences were not statistically significant. Thus, we conclude that tuberculosis disease affected survival but not occurrence of subsequent opportunistic infections or rate of CD4+ count decline. To assess the role of tuberculosis disease on the course of HTV infection, the ideal study design would compare HTV disease progression of tuberculosis patients and patients without tuberculosis in an incident cohort followed prospectively from HIV seroconversion. Although our study was a prevalent cohort for HIV infection, we have compared HIV-infected patients with a similar degree of immunodepression (baseline CD4+ lymphocyte count) and duration of known HIV infection (i.e., same year of HTV diagnosis). We also believe that care was comparable between the two groups because of the homogeneity of practices among the clinicians of the Aquitaine Cohort.
In our sample, the fact that tuberculosis patients had more frequent histories of AIDS-defining opportunistic infections at inclusion than controls, despite similar CD4+ lymphocyte counts, suggests a more clinically advanced HTV infection in tuberculosis patients. This discrepancy between biology and clinic confirms the fact, previously reported, that one measure of CD4+ lymphocyte count is insufficient to evaluate the progression of HIV infection (34) ; this is particularly true if tuberculosis infection tends to induce by itself a loss of CD4+ lymphocytes (16) . This might have masked a different evolution between the two groups. However, adjustment by proportional hazard regression including clinical and biologic determinants of HTV disease progression allowed us to take into account this potentially confounding factor. If the CD4+ lymphocyte counts were temporarily reduced at the time of tuberculosis diagnosis, a better baseline would have been to take into account the subsequent higher CD4+ count in tuberculosis patients. Doing this would only have increased the survival difference between the two groups.
The diagnosis of tuberculosis disease was confirmed in patients with clinical suspicion of tuberculosis, but this systematic investigation could not be made in controls. However, we guaranteed a minimal follow-up in all patients, and we have cross-checked all tuberculosis cases declared to the Department of Microbiology of the Bordeaux University Hospital with the Aquitaine Cohort data file. Thus, this selection problem was probably not important in our cohort and is unlikely to mask a difference between the two groups.
The reduced survival in tuberculosis patients was a finding consistent over the different subgroup analyses, except in intravenous drug users and in patients with a history of AIDS-defining opportunistic infection. These two characteristics were precisely those altering the comparability of our groups at inclusion. These discrepancies suggest that intravenous drug users might die before the diagnosis of tuberculosis disease because of a different access to medical care. Similarly, patients with a history of opportunistic infection might die before the diagnosis of tuberculosis disease because of a more advanced HIV infection. Nevertheless, the history of opportunistic infection and the low CD4+ lymphocyte count level remained more strongly associated with mortality than with the occurrence of tuberculosis disease in the multivariate analysis.
The excess mortality in tuberculosis patients may be explained by deaths related to tuberculosis disease or to other complications of HIV infection. This high mortality may result from emergence of multidrug resistance, but we have reported elsewhere (35) that multidrug resistance was low in our cohort (1.7 percent of 59 tuberculosis patients). In addition, all patients diagnosed in our study had been treated for tuberculosis disease, except when they died early. All tuberculosis patients were treated in hospitals and monitored by experienced practitioners; but unfortunately, evaluation of compliance was not available in our study. Thus, we suggest that potential therapeutic problems could not explain all the excess mortality in tuberculosis patients, and we conclude that most of them died from associated HIV infection. Nevertheless, a late diagnosis of tuberculosis disease, which in turn would induce a delay in the specific treatment, may explain in part this excess mortality (13, 15, 36) .
With regard to interaction between tuberculosis disease and HTV infection, HIV-infected patients with tuberculosis disease appear to have a shorter survival than HTV-negative patients, despite an adequate antituberculosis therapy (8, 37) . In addition, our study has shown that tuberculosis disease was a strong factor of mortality among HIV-infected patients. This finding is consistent with previous studies that suggested the same effect of tuberculosis disease on mortality among HIV-infected patients (8, 15) . Indirectly, Pape et al. (14) , in Haiti, have shown that preventive therapy of tuberculosis disease with isoniazid appeared to delay the onset of HIV-related opportunistic infections and to prolong survival. However, their findings might also be explained by a positive influence of tuberculosis therapy on CD4+ lymphocyte counts (38) and by the lack of control for HIV progression. Recently, Whalen et al. (19) , in a study controlled for HTV progression, have demonstrated the same effect as in our study.
Because of the high early mortality rate in HIVinfected patients with tuberculosis disease, care providers following HIV-infected patients must maintain a high level of suspicion for tuberculosis disease, particularly in patients with increased risk of developing an active tuberculosis disease, like intravenous drug users (3, 13) . Unfortunately, intravenous drug users are difficult to follow; assuring compliance with primary tuberculosis prophylaxis is challenging in such patients.
We conclude that tuberculosis disease might be a marker of advanced immunosuppression in HIVinfected patients and a strong factor of mortality, particularly in patients with CD4+ lymphocyte counts of fewer than 200 cells/mm 3 . These findings provide an additional argument for a greater use of tuberculosis preventive therapy in HIV-infected patients (11) . Considering the occurrence of opportunistic infections, our study did not show an accelerated progression of HTV infection in relation to tuberculosis disease, in contrast to the findings of Whalen et al. (19) . With a similar study design, they have shown a greater occurrence of opportunistic infections in tuberculosis patients than in controls. This may be subject to detection bias and may affect their findings because tuberculosis patients may be followed more closely than controls. Unfortunately, they did not provide data about the follow-up CD4+ rate decline to support their results. Our results were congruent regarding the CD4+ count decline and the occurrence of opportunistic infections. However, in our study, death may have eliminated the persons whose CD4+ counts were falling fastest and whose risk of a subsequent opportunistic infection was the highest.
Considering these contrasting findings, additional studies are needed to explore the interaction between tuberculosis disease and HTV infection. With this objective, studies that also use measurements of the viral load would be very informative (39) .
